J
Jean Paul Bahary
Researcher at Université de Montréal
Publications - 21
Citations - 3116
Jean Paul Bahary is an academic researcher from Université de Montréal. The author has contributed to research in topics: Radiation therapy & Temozolomide. The author has an hindex of 17, co-authored 21 publications receiving 2404 citations. Previous affiliations of Jean Paul Bahary include McGill University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
Paul D. Brown,Paul D. Brown,Karla V. Ballman,Karla V. Ballman,Jane H. Cerhan,S. Keith Anderson,Xiomara W. Carrero,Anthony Whitton,Jeffrey Greenspoon,Ian F. Parney,Nadia N. Laack,Jonathan B. Ashman,Jean Paul Bahary,Costas G. Hadjipanayis,James J. Urbanic,Fred G. Barker,Elana Farace,Deepak Khuntia,Caterina Giannini,Jan C. Buckner,Evanthia Galanis,David Roberge +21 more
TL;DR: After resection of a brain metastasis, SRS radiosurgery should be considered one of the standards of care as a less toxic alternative to WBRT for this patient population.
Journal ArticleDOI
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner,Edward G. Shaw,Stephanie L. Pugh,Arnab Chakravarti,Mark R. Gilbert,Geoffrey R. Barger,Stephen W. Coons,Peter Ricci,Dennis E. Bullard,Paul D. Brown,Keith J. Stelzer,David Brachman,John H. Suh,Christopher J. Schultz,Jean Paul Bahary,Barbara Fisher,Barbara Fisher,Harold Kim,Albert Murtha,Erica Hlavin Bell,Minhee Won,Minesh P. Mehta,Walter J. Curran +22 more
TL;DR: In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone.
Journal ArticleDOI
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
William U. Shipley,W. Seiferheld,H. Lukka,Pierre Major,Niall M. Heney,David J. Grignon,Oliver Sartor,Maltibehn P. Patel,Jean Paul Bahary,Anthony L. Zietman,Thomas M. Pisansky,Kenneth L. Zeitzer,Colleen A. Lawton,Felix Y. Feng,Richard Dana Lovett,Alexander Balogh,Luis Souhami,Seth A. Rosenthal,Kevin J. Kerlin,James J. Dignam,Stephanie L. Pugh,Howard M. Sandler +21 more
TL;DR: The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long‐term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo.
Journal ArticleDOI
Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of radiation therapy oncology group protocol 90-05
Edward G. Shaw,Charles Scott,Luis Souhami,Robert P. Dinapoli,Jean Paul Bahary,Robert W. Kline,Moody D. Wharam,Christopher J. Schultz,P. Davey,Jay S. Loeffler,John D Del Rowe,Lawrence B. Marks,Barbara Fisher,Kyu H. Shin +13 more
TL;DR: The incidence of acute toxicity was acceptable at 0-7% in patients with recurrent, previously irradiated primary brain tumors or brain metastases treated according to the protocol described, and the maximum acutely tolerable dose of single fraction radiosurgery was determined.
Journal ArticleDOI
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
Abdenour Nabid,Nathalie Carrier,André-Guy Martin,Jean Paul Bahary,Céline Lemaire,Sylvie Vass,Boris Bahoric,Robert Archambault,François Vincent,Redouane Bettahar,Marie Duclos,Marie Pierre Garant,Luis Souhami +12 more
TL;DR: Outcomes from high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 mo of androgen deprivation therapy showed no difference in survival between the two groups, with the 18-mo group experiencing a better quality of life.